Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28887798 | 0.86 | CYP4F2 (0.55) | CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL22070770 | 0.84 | CYP4F2 (0.59) | CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL11659511 | 0.81 | LMNA (0.38) | MEN1KMT2A | |
| SCHEMBL22070880 | 0.81 | CYP4F2 (0.54) | CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL11134602 | 0.78 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL11138355 | 0.76 | MEN1 (0.33) | MEN1KMT2AGCK | |
| SCHEMBL11137577 | 0.75 | MEN1 (0.32) | MEN1KMT2AGCK | |
| SCHEMBL11152390 | 0.75 | TBXAS1 (0.40) | MEN1KMT2AGCK | |
| SCHEMBL7881560 | 0.74 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL1513547 | 0.74 | MEN1 (0.36) | MEN1KMT2AGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | CYP4F2 633/4885CYP4A11 118/4885MEN1 1291/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | CYP4F2 733/4885CYP4A11 118/4885MEN1 1359/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | CYP4F2 727/4885CYP4A11 126/4885MEN1 1356/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | CYP4F2 727/4885CYP4A11 126/4885MEN1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.